SECOND REGULAR SESSION
SENATE BILL NO. 1165
102ND GENERA L ASSEMBLY
INTRODUCED BY SENATOR SCHROER.
3833S.02I KRISTINA MARTIN, Secretary
AN ACT
To repeal section 195.017, RSMo, and to enact in lieu thereof two new sections relating to
marijuana, with a penalty provision.
Be it enacted by the General Assembly of the State of Missouri, as follows:
1 Section A. Section 195.017, RSMo, is repealed and two new
2 sections enacted in lieu thereof, to be known as sections
3 195.017 and 195.810, to read as follows:
1 195.017. 1. The department of health and senior
2 services shall place a substance in Schedule I if it finds
3 that the substance:
4 (1) Has high potential for abuse; and
5 (2) Has no accepted medical use in treatment in the
6 United States or lacks accepted safety for use in treatment
7 under medical supervision.
8 2. Schedule I:
9 (1) The controlled substances listed in this
10 subsection are included in Schedule I;
11 (2) Any of the following opiates, including their
12 isomers, esters, ethers, salts, and salts of isomers,
13 esters, and ethers, unless specifically excepted, whenever
14 the existence of these isomers, esters, ethers and salts is
15 possible within the specific chemical designation:
16 (a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-
17 phenethyl)-4-piperidinyl)-N-phenylacetamide);
18 (b) Acetylmethadol;
SB 1165 2
19 (c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
20 phenylacetamide);
21 (d) Acryl fentanyl (-(1-phenethylpiperidin-4-yl)-N-
22 phenylacrylamide);
23 (e) AH-7921(3,4-dichloro-N-[(1-dimethylamino)
24 cyclohexylmethyl] benzamide);
25 (f) Allylprodine;
26 (g) Alphacetylmethadol (except levoalphacetylmethadol,
27 also known as levo-alpha-acetylmethadol levothadyl acetate
28 or LAAM);
29 (h) Alphameprodine;
30 (i) Alphamethadol;
31 (j) Alpha-methylfentanyl (N-1-(alphamethyl-beta-
32 phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-
33 phenylethyl)-4 ((N-propanilido) piperidine);
34 (k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2-
35 thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide);
36 (l) Benzethidine;
37 (m) Betacetylmethadol;
38 (n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-
39 4-piperidinyl)-N-phenylpropanamide);
40 (o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-
41 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide);
42 (p) Betameprodine;
43 (q) Betamethadol;
44 (r) Betaprodine;
45 (s) Clonitazene;
46 (t) Dextromoramide;
47 (u) Diampromide;
48 (v) Cyclopropyl fentanyl;
49 (w) Diethylthiambutene;
50 (x) Difenoxin;
SB 1165 3
51 (y) Dimenoxadol;
52 (z) Dimepheptanol;
53 (aa) Dimethylthiambutene;
54 (bb) Dioxaphetyl butyrate;
55 (cc) Dipipanone;
56 (dd) Ethylmethylthiambutene;
57 (ee) Etonitazene;
58 (ff) Etoxeridine;
59 (gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N-
60 (1-phenethylpiperidin-4-yl)isobutyramide;
61 (hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N-
62 phenylfuran-2-carboxamide;
63 (ii) Furethidine;
64 (jj) Hydroxypethidine;
65 (kk) Ketobemidone;
66 (ll) Levomoramide;
67 (mm) Levophenacylmorphan;
68 (nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-
69 piperidyl)-N-phenylproanamide), its optical and geometric
70 isomers, salts, and salts of isomers;
71 (oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2-
72 thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide);
73 (pp) Methoxyacetyl fentanyl (2-methoxy-N-(1-
74 phenethylpiperidin-4-yl)-N-phenylacetamide);
75 (qq) Morpheridine;
76 (rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
77 (ss) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl)
78 piperazine);
79 (tt) Noracymethadol;
80 (uu) Norlevorphanol;
81 (vv) Normethadone;
82 (ww) Norpipanone;
SB 1165 4
83 (xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1-
84 phenethylpiperidin-4-yl)acetamide;
85 (yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin-
86 yl)propionamide); other name 2-fluorofentanyl;
87 (zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N-
88 (1-phenethylpiperidin-4-yl)butyramide;
89 (aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2-
90 phenethyl)-4-piperidinyl) propanamide;
91 (bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4-
92 acetoxypiperidine);
93 (ccc) Phenadoxone;
94 (ddd) Phenampromide;
95 (eee) Phenomorphan;
96 (fff) Phenoperidine;
97 (ggg) Piritramide;
98 (hhh) Proheptazine;
99 (iii) Properidine;
100 (jjj) Propiram;
101 (kkk) Racemoramide;
102 (lll) Tetrahydrofuranyl fentanyl (N-(1-
103 phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
104 carboxamide);
105 (mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4-
106 piperidinyl)-propanamide;
107 (nnn) Tilidine;
108 (ooo) Trimeperidine;
109 (3) Any of the following opium derivatives, their
110 salts, isomers and salts of isomers unless specifically
111 excepted, whenever the existence of these salts, isomers and
112 salts of isomers is possible within the specific chemical
113 designation:
114 (a) Acetorphine;
SB 1165 5
115 (b) Acetyldihydrocodeine;
116 (c) Benzylmorphine;
117 (d) Codeine methylbromide;
118 (e) Codeine-N-Oxide;
119 (f) Cyprenorphine;
120 (g) Desomorphine;
121 (h) Dihydromorphine;
122 (i) Drotebanol;
123 (j) Etorphine (except hydrochloride salt);
124 (k) Heroin;
125 (l) Hydromorphinol;
126 (m) Methyldesorphine;
127 (n) Methyldihydromorphine;
128 (o) Morphine methylbromide;
129 (p) Morphine methylsulfonate;
130 (q) Morphine-N-Oxide;
131 (r) Myrophine;
132 (s) Nicocodeine;
133 (t) Nicomorphine;
134 (u) Normorphine;
135 (v) Pholcodine;
136 (w) Thebacon;
137 (4) Any of the following opiate similar synthetic
138 substances scheduled by the U.S. Drug Enforcement
139 Administration as substances that share a pharmacological
140 profile similar to fentanyl, morphine, and other synthetic
141 opioids, unless specifically excepted or unless listed in
142 another schedule:
143 (a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
144 phenylbutyramide);
145 (b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino)
146 cyclohexyl]--methyl benzamide).
SB 1165 6
147 (5) Any material, compound, mixture or preparation
148 which contains any quantity of the following hallucinogenic
149 substances, their salts, isomers and salts of isomers,
150 unless specifically excepted, whenever the existence of
151 these salts, isomers, and salts of isomers is possible
152 within the specific chemical designation:
153 (a) Alpha-ethyltryptamine;
154 (b) 4-bromo-2,5-dimethoxyamphetamine;
155 (c) 4-bromo-2,5-dimethoxyphenethylamine;
156 (d) 2,5-dimethoxyamphetamine;
157 (e) 2,5-dimethoxy-4-ethylamphetamine;
158 (f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
159 (g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;
160 (h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;
161 (i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;
162 (j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;
163 (k) 2-(2,5-Dimethoxyphenyl) ethanamine;
164 (l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;
165 (m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;
166 (n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;
167 (o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl)
168 ethanamine;
169 (p) 4-methoxyamphetamine;
170 (q) 5-methoxy-3,4-methylenedioxyamphetamine;
171 (r) 4-methyl-2, 5-dimethoxyamphetamine;
172 (s) 3,4-methylenedioxyamphetamine;
173 (t) 3,4-methylenedioxymethamphetamine;
174 (u) 3,4-methylenedioxy-N-ethylamphetamine;
175 (v) N-hydroxy-3, 4-methylenedioxyamphetamine;
176 (w) 3,4,5-trimethoxyamphetamine;
177 (x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine;
178 (y) Alpha-methyltryptamine;
SB 1165 7
179 (z) Bufotenine;
180 (aa) Diethyltryptamine;
181 (bb) Dimethyltryptamine;
182 (cc) 5-methoxy-N,N-diisopropyltryptamine;
183 (dd) Ibogaine;
184 (ee) Lysergic acid diethylamide;
185 (ff) Marijuana or marihuana, except industrial hemp
186 and except as permitted under article XIV of the
187 Constitution of Missouri;
188 (gg) Mescaline;
189 (hh) Parahexyl;
190 (ii) Peyote, to include all parts of the plant
191 presently classified botanically as Lophophora williamsii
192 Lemaire, whether growing or not; the seeds thereof; any
193 extract from any part of such plant; and every compound,
194 manufacture, salt, derivative, mixture or preparation of the
195 plant, its seed or extracts;
196 (jj) N-ethyl-3-piperidyl benzilate;
197 (kk) N-methyl-3-piperidyl benzilate;
198 (ll) Psilocybin;
199 (mm) Psilocyn;
200 (nn) Tetrahydrocannabinols naturally contained in a
201 plant of the genus Cannabis (cannabis plant), except
202 industrial hemp and except as permitted under article XIV of
203 the Constitution of Missouri, as well as synthetic
204 equivalents of the substances contained in the cannabis
205 plant, or in the resinous extractives of such plant, or
206 synthetic substances, derivatives and their isomers, or
207 both, with similar chemical structure and pharmacological
208 activity to those substances contained in the plant, such as
209 the following:
SB 1165 8
210 a. 1 cis or trans tetrahydrocannabinol and their
211 optical isomers;
212 b. 6 cis or trans tetrahydrocannabinol and their
213 optical isomers;
214 c. 3,4 cis or trans tetrahydrocannabinol and their
215 optical isomers;
216 d. Any compounds of these structures, regardless of
217 numerical designation of atomic positions covered;
218 (oo) Ethylamine analog of phencyclidine;
219 (pp) Pyrrolidine analog of phencyclidine;
220 (qq) Thiophene analog of phencyclidine;
221 (rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
222 (ss) Salvia divinorum;
223 (tt) Salvinorin A;
224 (uu) Synthetic cannabinoids:
225 a. Any compound structurally derived from 3-(1-
226 naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by
227 substitution at the nitrogen atom of the indole ring by
228 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
229 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
230 morpholinyl)ethyl group, whether or not further substituted
231 in the indole ring to any extent, whether or not substituted
232 in the naphthyl ring to any extent. Including, but not
233 limited to:
234 (i) AM2201, or 1-(5-fluoropentyl)-3-(1-
235 naphthoyl)indole;
236 (ii) JWH-007, or 1-pentyl-2-methyl-3-(1-
237 naphthoyl)indole;
238 (iii) JWH-015, or 1-propyl-2-methyl-3-(1-
239 naphthoyl)indole;
240 (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
241 (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
SB 1165 9
242 (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
243 (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-
244 naphthoyl)indole;
245 (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-
246 naphthoyl)indole;
247 (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-
248 naphthoyl)indole;
249 (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-
250 naphthoyl)indole;
251 (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-
252 naphthoyl)indole;
253 (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-
254 naphthoyl)indole;
255 (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-
256 naphthoyl)indole;
257 b. Any compound structurally derived from 3-(1-
258 naphthoyl)pyrrole by substitution at the nitrogen atom of
259 the pyrrole ring by alkyl, haloalkyl, alkenyl,
260 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
261 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether
262 or not further substituted in the pyrrole ring to any
263 extent, whether or not substituted in the naphthyl ring to
264 any extent;
265 c. Any compound structurally derived from 1-(1-
266 naphthylmethyl)indene by substitution at the 3-position of
267 the indene ring by alkyl, haloalkyl, alkenyl,
268 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
269 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether
270 or not further substituted in the indene ring to any extent,
271 whether or not substituted in the naphthyl ring to any
272 extent;
SB 1165 10
273 d. Any compound structurally derived from 3-
274 phenylacetylindole by substitution at the nitrogen atom of
275 the indole ring with alkyl, haloalkyl, alkenyl,
276 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
277 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether
278 or not further substituted in the indole ring to any extent,
279 whether or not substituted in the phenyl ring to any
280 extent. Including, but not limited to:
281 (i) JWH-201, or 1-pentyl-3-(4-
282 methoxyphenylacetyl)indole;
283 (ii) JWH-203, or 1-pentyl-3-(2-
284 chlorophenylacetyl)indole;
285 (iii) JWH-250, or 1-pentyl-3-(2-
286 methoxyphenylacetyl)indole;
287 (iv) JWH-251, or 1-pentyl-3-(2-
288 methylphenylacetyl)indole;
289 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-
290 methoxyphenylacetyl)indole;
291 e. Any compound structurally derived from 2-(3-
292 hydroxycyclohexyl)phenol by substitution at the 5-position
293 of the phenolic ring by alkyl, haloalkyl, alkenyl,
294 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
295 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether
296 or not substituted in the cyclohexyl ring to any extent.
297 Including, but not limited to CP 47, 497 and homologues, or
298 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-
299 yl)phenol, where side chain n=5, and homologues where side
300 chain n-4,6, or 7;
301 f. Any compound containing a 3-(benzoyl)indole
302 structure with substitution at the nitrogen atom of the
303 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
304 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
SB 1165 11
305 morpholinyl)ethyl group, whether or not further substituted
306 in the indole ring to any extent and whether or not
307 substituted in the phenyl ring to any extent. Including,
308 but not limited to:
309 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-
310 iodobenzoyl)indole;
311 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-
312 19 and RCS-4);
313 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-
314 methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-
315 octahydrophenanthridin-1-yl] acetate;
316 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-
317 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
318 tetrahydrobenzo[c]chromen-1-ol;
319 i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-
320 6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
321 tetrahydrobenzo[c]chromen-1-ol;
322 j. Dimethylheptylpyran, or DMHP;
323 (6) Any material, compound, mixture or preparation
324 containing any quantity of the following substances having a
325 depressant effect on the central nervous system, including
326 their salts, isomers and salts of isomers whenever the
327 existence of these salts, isomers and salts of isomers is
328 possible within the specific chemical designation:
329 (a) Gamma-hydroxybutyric acid;
330 (b) Mecloqualone;
331 (c) Methaqualone;
332 (7) Any material, compound, mixture or preparation
333 containing any quantity of the following substances having a
334 stimulant effect on the central nervous system, including
335 their salts, isomers and salts of isomers:
336 (a) Aminorex;
SB 1165 12
337 (b) N-benzylpiperazine;
338 (c) Cathinone;
339 (d) Fenethylline;
340 (e) 3-Fluoromethcathinone;
341 (f) 4-Fluoromethcathinone;
342 (g) Mephedrone, or 4-methylmethcathinone;
343 (h) Methcathinone;
344 (i) 4-methoxymethcathinone;
345 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-
346 methyl-5-phenyl-2-oxazolamine);
347 (k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3-
348 Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;
349 (l) Methylone, or 3,4-Methylenedioxymethcathinone;
350 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
351 (n) N-ethylamphetamine;
352 (o) N,N-dimethylamphetamine;
353 (p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
354 22; QUPIC);
355 (q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
356 carboxylate (5-fluoro-PB-22; 5F-PB-22);
357 (r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
358 fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);
359 (s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-
360 1H-indazole-3-carboxamide (ADB-PINACA);
361 (8) A temporary listing of substances subject to
362 emergency scheduling under federal law shall include any
363 material, compound, mixture or preparation which contains
364 any quantity of the following substances:
365 (a) (1-pentyl-1H-indol-3-yl)(2,2,3,3-
366 tetramethylcyclopropyl)methanone, its optical, positional,
367 and geometric isomers, salts, and salts of isomers;
SB 1165 13
368 (b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-
369 tetramethylcyclopropyl)methanone, its optical, positional,
370 and geometric isomers, salts, and salts of isomers;
371 (c) N-(1-adamantyl)-1-pentyl-1H-indazole-3-
372 carboxamide, its optical, positional, and geometric isomers,
373 salts, and salts of isomers;
374 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
375 methoxybenzyl)ethanamine, its optical, positional, and
376 geometric isomers, salts, and salts of isomers;
377 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
378 methoxybenzyl)ethanamine, its optical, positional, and
379 geometric isomers, salts, and salts of isomers;
380 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
381 methoxybenzyl)ethanamine, its optical, positional, and
382 geometric isomers, salts, and salts of isomers;
383 (g) 4-methyl-N-ethylcathinone, its optical,
384 positional, and geometric isomers, salts, and salts of
385 isomers;
386 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its
387 optical, positional, and geometric isomers, salts, and salts
388 of isomers;
389 (i) Alpha-pyrrolidinopentiophenone, its optical,
390 positional, and geometric isomers, salts, and salts of
391 isomers;
392 (j) Butylone, its optical, positional, and geometric
393 isomers, salts, and salts of isomers;
394 (k) Pentedrone, its optical, positional, and geometric
395 isomers, salts, and salts of isomers;
396 (l) Pentylone, its optical, positional, and geometric
397 isomers, salts, and salts of isomers;
398 (m) Naphyrone, its optical, positional, and geometric
399 isomers, salts, and salts of isomers;
SB 1165 14
400 (n) Alpha-pyrrolidinobutiophenone, its optical,
401 positional, and geometric isomers, salts, and salts of
402 isomers;
403 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
404 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,
405 positional, and geometric isomers, salts, and salts of
406 isomers;
407 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
408 indazole-3-carboxamide, its optical, positional, and
409 geometric isomers, salts, and salts of isomers;
410 (q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1-
411 yl)methanone, its optical, positional, and geometric
412 isomers, salts, and salts of isomers;
413 (r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-
414 4-yl]-N-phenylpropionamide, its isomers, esters, ethers,
415 salts, and salts of isomers, esters, and ethers;
416 (s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
417 its optical, positional, and geometric isomers, salts, and
418 salts of isomers;
419 (t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
420 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,
421 positional, and geometric isomers, salts, and salts of
422 isomers;
423 (u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
424 carboxamido)-3,3-dimethylbutanoate, its optical, positional,
425 and geometric isomers, salts, and salts of isomers;
426 (v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
427 carboxamido)-3-methylbutanoate, its optical, positional, and
428 geometric isomers, salts, and salts of isomers;
429 (w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-
430 3-carboxamide, its optical, positional, and geometric
431 isomers, salts, and salts of isomers;
SB 1165 15
432 (x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
433 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
434 positional, and geometric isomers, salts, and salts of
435 isomers;
436 (y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
437 carboxamido)-3,3-dimethylbutanoate, its optical, positional,
438 and geometric isomers, salts, and salts of isomers;
439 (z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-
440 carboxamido)-3,3-dimethylbutanoate, its optical, positional,
441 and geometric isomers, salts, and salts of isomers;
442 (aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
443 yl)propionamide, its isomers, esters, ethers, salts, and
444 salts of isomers, esters, and ethers;
445 (bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-
446 carboxamido)-3-methylbutanoate, its optical, positional, and
447 geometric isomers, salts, and salts of isomers;
448 (cc) N-(1-phenethylpiperidin-4-yl)-N-
449 phenylcyclopropanecarboxamide, its isomers, esters, ethers,
450 salts, and salts of isomers, esters, and ethers;
451 (dd) N-(1-phenethylpiperidin-4-yl)-N-
452 phenylpentanamide, its isomers, esters, ethers, salts, and
453 salts of isomers, esters, and ethers;
454 (ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-
455 yl)butyramide, its isomers, esters, ethers, salts, and salts
456 of isomers, esters, and ethers;
457 (ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
458 yl)butyramide, its isomers, esters, ethers, salts, and salts
459 of isomers, esters, and ethers;
460 (gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
461 yl)isobutyramide, its isomers, esters, ethers, salts, and
462 salts of isomers, esters, and ethers;
SB 1165 16
463 (hh) N-(1-phenethylpiperidin-4-yl)-N-
464 phenylisobutyramide, its isomers, esters, ethers, salts, and
465 salts of isomers, esters, and ethers;
466 (ii) N-(1-phenethylpiperidin-4-yl)-N-
467 phenylcyclopentanecarboxamide, its isomers, esters, ethers,
468 salts, and salts of isomers, esters, and ethers;
469 (jj) Fentanyl-related substances, their isomers,
470 esters, ethers, salts, and salts of isomers, esters, and
471 ethers. Fentanyl-related substance shall mean any substance
472 not otherwise listed under another Drug Enforcement
473 Administration Controlled Substance Code Number, and for
474 which no exemption or approval is in effect under section
475 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
476 Section 355, that is structurally related to fentanyl by one
477 or more of the following modifications:
478 a. Replacement of the phenyl portion of the phenethyl
479 group by any monocycle, whether or not further substituted
480 in or on the monocycle;
481 b. Substitution in or on the phenethyl group with
482 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or
483 nitro groups;
484 c. Substitution in or on the piperidine ring with
485 alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, amino or
486 nitro groups;
487 d. Replacement of the aniline ring with any aromatic
488 monocycle, whether or not further substituted in or on the
489 aromatic monocycle; or
490 e. Replacement of the N-propionyl group by another
491 acyl group;
492 (kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
493 carboxylate, its optical, positional, and geometric isomers,
494 salts, and salts of isomers (NM2201; CBL2201);
SB 1165 17
495 (ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
496 fluoropentyl)-1H-indazole-3-carboxamide, its optical,
497 positional, and geometric isomers, salts, and salts of
498 isomers (5F-AB-PINACA);
499 (mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-
500 indazole-3-carboxamide, its optical, positional, and
501 geometric isomers, salts, and salts of isomers (4-CN-CUMYL-
502 BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-
503 4CN-BINACA; SGT-78);
504 (nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
505 carboxamido)-3-methylbutanoate, its optical, positional, and
506 geometric isomers, salts, and salts of isomers (MMB-CHMICA,
507 AMB-CHMICA);
508 (oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
509 pyrrolo[2,3-b]pyridine-3-carboxamide, its optical,
510 positional, and geometric isomers, salts, and salts of
511 isomers (5F-CUMYL-P7AICA);
512 (pp) N-ethylpentylone, its optical, positional, and
513 geometric isomers, salts, and salts of isomers (ephylone, 1-
514 (1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one;
515 (qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
516 carboxamido)-3,3-dimethylbutanoate, its optical, positional,
517 and geometric isomers, salts, and salts of isomers (trivial
518 name: 5F-EDMB-PINACA);
519 (rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-
520 carboxamido)-3,3-dimethylbutanoate, its optical, positional,
521 and geometric isomers, salts, and salts of isomers (trivial
522 name: 5F-MDMB-PICA);
523 (ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-
524 3-carboxamide, its optical, positional, and geometric
525 isomers, salts, and salts of isomers (trivial names: FUB-
526 AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL));
SB 1165 18
527 (tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
528 indazole-3-carboxamide, its optical, positional, and
529 geometric isomers, salts, and salts of isomers (trivial
530 names: 5F-CUMYL-PINACA; SGT-25);
531 (uu) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
532 tetramethylcyclopropyl) methanone, its optical, positional,
533 and geometric isomers, salts, and salts of isomers (trivial
534 name: FUB-144);
535 (vv) N-ethylhexedrone, its optical, positional, and
536 geometric isomers, salts, and salts of isomers (Other name:
537 2-(ethylamino)-1-phenylhexan-1-one);
538 (ww) alpha-pyrrolidinohexanophenone, its optical,
539 positional, and geometric isomers, salts, and salts of
540 isomers (Other names: α-PHP; alpha-pyrrolidinohexiophenone;
541 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
542 (xx) 4-methyl-alpha-ethylaminopentiophenone, its
543 optical, positional, and geometric isomers, salts, and salts
544 of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4-
545 methylphenyl)pentan-1-one);
546 (yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its
547 optical, positional, and geometric isomers, salts, and salts
548 of isomers (Other names: MPHP; 4'-methyl-alpha-
549 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-
550 yl)hexan-1-one);
551 (zz) alpha-pyrrolidinoheptaphenone, its optical,
552 positional, and geometric isomers, salts, and salts of
553 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-
554 yl)heptan-1-one);
555 (aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its
556 optical, positional, and geometric isomers, salts, and salts
557 of isomers (Other names: 4-chloro-α-PVP; 4'-chloro-alpha-
SB 1165 19
558 pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-
559 yl)pentan-1-one);
560 (9) Khat, to include all parts of the plant presently
561 classified botanically as catha edulis, whether growing or
562 not; the seeds thereof; any extract from any part of such
563 plant; and every compound, manufacture, salt, derivative,
564 mixture, or preparation of the plant, its seed or extracts.
565 3. The department of health and senior services shall
566 place a substance in Schedule II if it finds that:
567 (1) The substance has high potential for abuse;
568 (2) The substance has currently accepted medical use
569 in treatment in the United States, or currently accepted
570 medical use with severe restrictions; and
571 (3) The abuse of the substance may lead to severe
572 psychic or physical dependence.
573 4. The controlled substances listed in this subsection
574 are included in Schedule II:
575 (1) Any of the following substances whether produced
576 directly or indirectly by extraction from substances of
577 vegetable origin, or independently by means of chemical
578 synthesis, or by combination of extraction and chemical
579 synthesis:
580 (a) Opium and opiate; and any salt, compound,
581 derivative or preparation of opium or opiate, excluding
582 apomorphine, thebaine-derived butorphanol, dextrorphan,
583 nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone,
584 and their respective salts, but including the following:
585 a. Raw opium;
586 b. Opium extracts;
587 c. Opium fluid;
588 d. Powdered opium;
589 e. Granulated opium;
SB 1165 20
590 f. Tincture of opium;
591 g. Codeine;
592 h. Dihydroetorphine;
593 i. Ethylmorphine;
594 j. Etorphine hydrochloride;
595 k. Hydrocodone;
596 l. Hydromorphone;
597 m. Metopon;
598 n. Morphine;
599 o. Oripavine;
600 p. Oxycodone;
601 q. Oxymorphone;
602 r. Thebaine;
603 (b) Any salt, compound, derivative, or preparation
604 thereof which is chemically equivalent or identical with any
605 of the substances referred to in this subdivision, but not
606 including the isoquinoline alkaloids of opium;
607 (c) Opium poppy and poppy straw;
608 (d) Coca leaves and any salt, compound, derivative, or
609 preparation of coca leaves, and any salt, compound,
610 derivative, or preparation thereof which is chemically
611 equivalent or identical with any of these substances, but
612 not including the following:
613 a. Decocainized coca leaves or extractions of coca
614 leaves, which extractions do not contain cocaine or
615 ecgonine; or
616 b. Ioflupane;
617 (e) Concentrate of poppy straw (the crude extract of
618 poppy straw in either liquid, solid or powder form which
619 contains the phenanthrene alkaloids of the opium poppy);
620 (2) Any of the following opiates, including their
621 isomers, esters, ethers, salts, and salts of isomers,
SB 1165 21
622 whenever the existence of these isomers, esters, ethers, and
623 salts is possible within the specific chemical designation,
624 dextrorphan and levopropoxyphene excepted:
625 (a) Alfentanil;
626 (b) Alphaprodine;
627 (c) Anileridine;
628 (d) Bezitramide;
629 (e) Bulk dextropropoxyphene;
630 (f) Carfentanil;
631 (g) Dihydrocodeine;
632 (h) Diphenoxylate;
633 (i) Fentanyl;
634 (j) Isomethadone;
635 (k) Levo-alphacetylmethadol;
636 (l) Levomethorphan;
637 (m) Levorphanol;
638 (n) Metazocine;
639 (o) Methadone;
640 (p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,
641 4-diphenylbutane;
642 (q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-
643 diphenylpropane-carboxylic acid;
644 (r) Pethidine (meperidine);
645 (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
646 phenylpiperidine;
647 (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-
648 4-carboxylate;
649 (u) Pethidine-Intermediate-C, 1-methyl-4-
650 phenylpiperdine-4-carboxylic acid;
651 (v) Phenazocine;
652 (w) Piminodine;
653 (x) Racemethorphan;
SB 1165 22
654 (y) Racemorphan;
655 (z) Remifentanil;
656 (aa) Sufentanil;
657 (bb) Tapentadol;
658 (cc) Thiafentanil;
659 (3) Any material, compound, mixture, or preparation
660 which contains any quantity of the following substances
661 having a stimulant effect on the central nervous system:
662 (a) Amphetamine, its salts, optical isomers, and salts
663 of its optical isomers;
664 (b) Lisdexamfetamine, its salts, isomers, and salts of
665 its isomers;
666 (c) Methamphetamine, its salts, isomers, and salts of
667 its isomers;
668 (d) Phenmetrazine and its salts;
669 (e) Methylphenidate;
670 (4) Any material, compound, mixture, or preparation
671 which contains any quantity of the following substances
672 having a depressant effect on the central nervous system,
673 including its salts, isomers, and salts of isomers whenever
674 the existence of those salts, isomers, and salts of isomers
675 is possible within the specific chemical designation:
676 (a) Amobarbital;
677 (b) Glutethimide;
678 (c) Pentobarbital;
679 (d) Phencyclidine;
680 (e) Secobarbital;
681 (5) Hallucinogenic substances:
682 (a) Any material or compound which contains any
683 quantity of nabilone;
SB 1165 23
684 (b) Dronabinol [(-)-Δ-9-trans tetrahydrocannabinol] in
685 an oral solution in a drug product approved for marketing by
686 the U.S. Food and Drug Administration;
687 (6) Any material, compound, mixture, or preparation
688 which contains any quantity of the following substances:
689 (a) Immediate precursor to amphetamine and
690 methamphetamine: Phenylacetone;
691 (b) Immediate precursors to phencyclidine (PCP):
692 a. 1-phenylcyclohexylamine;
693 b. 1-piperidinocyclohexanecarbonitrile (PCC);
694 (c) Immediate precursor to fentanyl: 4-anilino-N-
695 phenethyl-4-piperidine (ANPP);
696 (7) Any material, compound, mixture, or preparation
697 which contains any quantity of the following alkyl nitrites:
698 (a) Amyl nitrite;
699 (b) Butyl nitrite.
700 5. The department of health and senior services shall
701 place a substance in Schedule III if it finds that:
702 (1) The substance has a potential for abuse less than
703 the substances listed in Schedules I and II;
704 (2) The substance has currently accepted medical use
705 in treatment in the United States; and
706 (3) Abuse of the substance may lead to moderate or low
707 physical dependence or high psychological dependence.
708 6. The controlled substances listed in this subsection
709 are included in Schedule III:
710 (1) Any material, compound, mixture, or preparation
711 which contains any quantity of the following substances
712 having a potential for abuse associated with a stimulant
713 effect on the central nervous system:
714 (a) Benzphetamine;
715 (b) Chlorphentermine;
SB 1165 24
716 (c) Clortermine;
717 (d) Phendimetrazine;
718 (2) Any material, compound, mixture or preparation
719 which contains any quantity or salt of the following
720 substances or salts having a depressant effect on the
721 central nervous system:
722 (a) Any material, compound, mixture or preparation
723 which contains any quantity or salt of the following
724 substances combined with one or more active medicinal
725 ingredients:
726 a. Amobarbital;
727 b. Secobarbital;
728 c. Pentobarbital;
729 (b) Any suppository dosage form containing any
730 quantity or salt of the following:
731 a. Amobarbital;
732 b. Secobarbital;
733 c. Pentobarbital;
734 (c) Any substance which contains any quantity of a
735 derivative of barbituric acid or its salt;
736 (d) Chlorhexadol;
737 (e) Embutramide;
738 (f) Gamma hydroxybutyric acid and its salts, isomers,
739 and salts of isomers contained in a drug product for which
740 an application has been approved under Section 505 of the
741 federal Food, Drug, and Cosmetic Act;
742 (g) Ketamine, its salts, isomers, and salts of isomers;
743 (h) Lysergic acid;
744 (i) Lysergic acid amide;
745 (j) Methyprylon;
746 (k) Perampanel, and its salts, isomers, and salts of
747 isomers;
SB 1165 25
748 (l) Sulfondiethylmethane;
749 (m) Sulfonethylmethane;
750 (n) Sulfonmethane;
751 (o) Tiletamine and zolazepam or any salt thereof;
752 (3) Nalorphine;
753 (4) Any material, compound, mixture, or preparation
754 containing limited quantities of any of the following
755 narcotic drugs or their salts:
756 (a) Not more than 1.8 grams of codeine per one hundred
757 milliliters or not more than ninety milligrams per dosage
758 unit, with an equal or greater quantity of an isoquinoline
759 alkaloid of opium;
760 (b) Not more than 1.8 grams of codeine per one hundred
761 milliliters or not more than ninety milligrams per dosage
762 unit with one or more active, nonnarcotic ingredients in
763 recognized therapeutic amounts;
764 (c) Not more than 1.8 grams of dihydrocodeine per one
765 hundred milliliters or not more than ninety milligrams per
766 dosage unit, with one or more active, nonnarcotic
767 ingredients in recognized therapeutic amounts;
768 (d) Not more than three hundred milligrams of
769 ethylmorphine per one hundred milliliters or not more than
770 fifteen milligrams per dosage unit, with one or more active,
771 nonnarcotic ingredients in recognized therapeutic amounts;
772 (e) Not more than five hundred milligrams of opium per
773 one hundred milliliters or per one hundred grams or not more
774 than twenty-five milligrams per dosage unit, with one or
775 more active nonnarcotic ingredients in recognized
776 therapeutic amounts;
777 (f) Not more than fifty milligrams of morphine per one
778 hundred milliliters or per one hundred grams, with one or
SB 1165 26
779 more active, nonnarcotic ingredients in recognized
780 therapeutic amounts;
781 (5) Any material, compound, mixture, or preparation
782 containing any of the following narcotic drugs or their
783 salts: Buprenorphine;
784 (6) Anabolic steroids. Any drug or hormonal
785 substance, chemically and pharmacologically related to
786 testosterone (other than estrogens, progestins,
787 corticosteroids, and dehydroepiandrosterone) that promotes
788 muscle growth, except an anabolic steroid which is expressly
789 intended for administration through implants to cattle or
790 other nonhuman species and which has been approved by the
791 Secretary of Health and Human Services for that
792 administration. If any person prescribes, dispenses, or
793 distributes such steroid for human use, such person shall be
794 considered to have prescribed, dispensed, or distributed an
795 anabolic steroid within the meaning of this subdivision.
796 Unless specifically excepted or unless listed in another
797 schedule, any material, compound, mixture or preparation
798 containing any quantity of the following substances,
799 including its salts, esters and ethers:
800 (a) 3ß,17ß-dihydroxy-5α-androstane;
801 (b) 3α,17β-dihydroxy-5α-androstane;
802 (c) 5α-androstan-3,17-dione;
803 (d) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-
804 ene);
805 (e) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-
806 ene);
807 (f) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene);
808 (g) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene);
809 (h) 1-androstenedione ([5α]-androst-1-en-3,17-dione);
810 (i) 4-androstenedione (androst-4-en-3,17-dione);
SB 1165 27
811 (j) 5-androstenedione (androst-5-en-3,17-dione);
812 (k) Bolasterone (7α, 17α-dimethyl-17β-hydroxyandrost-4-
813 en-3-one);
814 (l) Boldenone (17β-hydroxyandrost-1,4,-diene-3-one);
815 (m) Boldione;
816 (n) Calusterone (7β, 17α-dimethyl-17β-hydroxyandrost-4-
817 en-3-one);
818 (o) Clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one);
819 (p) Dehydrochloromethyltestosterone (4-chloro-17β-
820 hydroxy-17α-methyl-androst-1,4-dien-3-one);
821 (q) Desoxymethyltestosterone;
822 (r) 4-dihydrotestosterone (17ß-hydroxy-androstan-3-
823 one);
824 (s) Drostanolone (17ß-hydroxy-2α-methyl-5α-androstan-3-
825 one);
826 (t) Ethylestrenol (17α-ethyl-17ß-hydroxyestr-4-ene);
827 (u) Fluoxymesterone (9-fluoro-17α-methyl-11ß,17ß-
828 dihydroxyandrost-4-en-3-one);
829 (v) Formebolone (2-formyl-17α-methyl-11α,17ß-
830 dihydroxyandrost-1,4-dien-3-one);
831 (w) Furazabol (17α-methyl-17ß-hydroxyandrostano[2,3-c]-
832 furazan);
833 (x) 13ß-ethyl-17ß-hydroxygon-4-en-3-one;
834 (y) 4-hydroxytestosterone (4,17ß-dihydroxy-androst-4-
835 en-3-one);
836 (z) 4-hydroxy-19-nortestosterone (4,17ß-dihydroxy-estr-
837 4-en-3-one);
838 (aa) Mestanolone (17α-methyl-17ß-hydroxy-5α-androstan-
839 3-one);
840 (bb) Mesterolone (1α- methyl-17ß-hydroxy-[5α]-
841 androstan-3-one);
SB 1165 28
842 (cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4-
843 dien-3-one);
844 (dd) Methandriol (17α-methyl-3ß,17ß-dihydroxyandrost-5-
845 ene);
846 (ee) Methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-
847 3-one);
848 (ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en-
849 3-one);
850 (gg) 17α-methyl-3β,17β-dihydroxy-5α-androstane;
851 (hh) 17α-methyl-3α,17β-dihydroxy-5α-androstane;
852 (ii) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;
853 (jj) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-
854 hydroxy-17β-hydroxyestr-4-en-3-one);
855 (kk) Methyldienolone (17α-methyl-17β-hydroxyestra-
856 4,9(10)-dien-3-one);
857 (ll) Methyltrienolone (17α-methyl-17β-hydroxyestra-
858 4,9,11-trien-3-one);
859 (mm) Methyltestosterone (17α-methyl-17β-hydroxyandrost-
860 4-en-3-one);
861 (nn) Mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-
862 3-one);
863 (oo) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-
864 17α-methyl-5α-androst-1-en-3-one) (a.k.a. '17-α-methyl-1-
865 testosterone');
866 (pp) Nandrolone (17β-hydroxyestr-4-ene-3-one);
867 (qq) 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4-
868 ene);
869 (rr) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-
870 ene);
871 (ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-
872 diene-3,17-dione);
SB 1165 29
873 (tt) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-
874 ene);
875 (uu) 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5-
876 ene);
877 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
878 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
879 (xx) Norbolethone (13β,17α-diethyl-17β-hydroxygon-4-en-
880 3-one);
881 (yy) Norclostebol (4-chloro-17β-hydroxyestr-4-en-3-
882 one);
883 (zz) Norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-
884 one);
885 (aaa) Normethandrolone (17α-methyl-17β-hydroxyestr-4-
886 en-3-one);
887 (bbb) Oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]-
888 androstan-3-one);
889 (ccc) Oxymesterone (17α-methyl-4,17β-dihydroxyandrost-
890 4-en-3-one);
891 (ddd) metholone (17α-methyl-2-hydroxymethylene-17β-
892 hydroxy-[5α]-androstan-3-one);
893 (eee) Prostanozol (17β-hydroxy-5α-androstano[3,2-
894 c]pyrazole);
895 (fff) Stanolone (Δ1-dihydrotestosterone (a.k.a. 1-
896 testosterone)(17β-hydroxy-5α-androst-1-en-3-one));
897 (ggg) Stanozolol (17α-methyl-17ß-hydroxy-[5α]-androst-
898 2-eno[3,2-c]-pyrazole);
899 (hhh) Stenbolone (17ß-hydroxy-2-methyl-[5α]-androst-1-
900 en-3-one);
901 (iii) Testolactone (13-hydroxy-3-oxo-13,17-
902 secoandrosta-1,4-dien-17-oic acid lactone);
903 (jjj) Testosterone (17ß-hydroxyandrost-4-en-3-one);
SB 1165 30
904 (kkk) Tetrahydrogestrinone (13ß,17α-diethyl-17ß-
905 hydroxygon-4,9,11-trien-3-one);
906 (lll) Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one);
907 (mmm) Any salt, ester, or ether of a drug or substance
908 described or listed in this subdivision, except an anabolic
909 steroid which is expressly intended for administration
910 through implants to cattle or other nonhuman species and
911 which has been approved by the Secretary of Health and Human
912 Services for that administration;
913 (7) Dronabinol (synthetic) in sesame oil and
914 encapsulated in a soft gelatin capsule in a United States
915 Food and Drug Administration approved drug product;
916 (8) The department of health and senior services may
917 except by rule any compound, mixture, or preparation
918 containing any stimulant or depressant substance listed in
919 subdivisions (1) and (2) of this subsection from the
920 application of all or any part of sections 195.010 to
921 195.320 if the compound, mixture, or preparation contains
922 one or more active medicinal ingredients not having a
923 stimulant or depressant effect on the central nervous
924 system, and if the admixtures are included therein in
925 combinations, quantity, proportion, or concentration that
926 vitiate the potential for abuse of the substances which have
927 a stimulant or depressant effect on the central nervous
928 system.
929 7. The department of health and senior services shall
930 place a substance in Schedule IV if it finds that:
931 (1) The substance has a low potential for abuse
932 relative to substances in Schedule III;
933 (2) The substance has currently accepted medical use
934 in treatment in the United States; and
SB 1165 31
935 (3) Abuse of the substance may lead to limited
936 physical dependence or psychological dependence relative to
937 the substances in Schedule III.
938 8. The controlled substances listed in this subsection
939 are included in Schedule IV:
940 (1) Any material, compound, mixture, or preparation
941 containing any of the following narcotic drugs or their
942 salts calculated as the free anhydrous base or alkaloid, in
943 limited quantities as set forth below:
944 (a) Not more than one milligram of difenoxin and not
945 less than twenty-five micrograms of atropine sulfate per
946 dosage unit;
947 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-
948 diphenyl-3-methyl-2-propionoxybutane);
949 (c) 2-[(dimethylamino)methyl]-1-(3-
950 methoxyphenyl)cyclohexanol, its salts, optical and geometric
951 isomers, and salts of these isomers (including tramadol);
952 (d) Any of the following limited quantities of
953 narcotic drugs or their salts, which shall include one or
954 more nonnarcotic active medicinal ingredients in sufficient
955 proportion to confer upon the compound, mixture or
956 preparation valuable medicinal qualities other than those
957 possessed by the narcotic drug alone:
958 a. Not more than two hundred milligrams of codeine per
959 one hundred milliliters or per one hundred grams;
960 b. Not more than one hundred milligrams of
961 dihydrocodeine per one hundred milliliters or per one
962 hundred grams;
963 c. Not more than one hundred milligrams of
964 ethylmorphine per one hundred milliliters or per one hundred
965 grams;
SB 1165 32
966 (2) Any material, compound, mixture or preparation
967 containing any quantity of the following substances,
968 including their salts, isomers, and salts of isomers
969 whenever the existence of those salts, isomers, and salts of
970 isomers is possible within the specific chemical designation:
971 (a) Alfaxalone;
972 (b) Alprazolam;
973 (c) Barbital;
974 (d) Bromazepam;
975 (e) Camazepam;
976 (f) Carisoprodol;
977 (g) Chloral betaine;
978 (h) Chloral hydrate;
979 (i) Chlordiazepoxide;
980 (j) Clobazam;
981 (k) Clonazepam;
982 (l) Clorazepate;
983 (m) Clotiazepam;
984 (n) Cloxazolam;
985 (o) Delorazepam;
986 (p) Diazepam;
987 (q) Dichloralphenazone;
988 (r) Estazolam;
989 (s) Ethchlorvynol;
990 (t) Ethinamate;
991 (u) Ethyl loflazepate;
992 (v) Fludiazepam;
993 (w) Flunitrazepam;
994 (x) Flurazepam;
995 (y) Fospropofol;
996 (z) Halazepam;
997 (aa) Haloxazolam;
SB 1165 33
998 (bb) Ketazolam;
999 (cc) Loprazolam;
1000 (dd) Lorazepam;
1001 (ee) Lormetazepam;
1002 (ff) Mebutamate;
1003 (gg) Medazepam;
1004 (hh) Meprobamate;
1005 (ii) Methohexital;
1006 (jj) Methylphenobarbital (mephobarbital);
1007 (kk) Midazolam;
1008 (ll) Nimetazepam;
1009 (mm) Nitrazepam;
1010 (nn) Nordiazepam;
1011 (oo) Oxazepam;
1012 (pp) Oxazolam;
1013 (qq) Paraldehyde;
1014 (rr) Petrichloral;
1015 (ss) Phenobarbital;
1016 (tt) Pinazepam;
1017 (uu) Prazepam;
1018 (vv) Quazepam;
1019 (ww) Suvorexant;
1020 (xx) Temazepam;
1021 (yy) Tetrazepam;
1022 (zz) Triazolam;
1023 (aaa) Zaleplon;
1024 (bbb) Zolpidem;
1025 (ccc) Zopiclone;
1026 (3) Any material, compound, mixture, or preparation
1027 which contains any quantity of the following substance
1028 including its salts, isomers and salts of isomers whenever
SB 1165 34
1029 the existence of such salts, isomers and salts of isomers is
1030 possible: fenfluramine;
1031 (4) Any material, compound, mixture, or preparation
1032 which contains any quantity of the following substances,
1033 including its salts, isomers, and salts of isomers, whenever
1034 the existence of such salts, isomers, and salts of isomers
1035 is possible: Lorcaserin;
1036 (5) Any material, compound, mixture or preparation
1037 containing any quantity of the following substances having a
1038 stimulant effect on the central nervous system, including
1039 their salts, isomers and salts of isomers:
1040 (a) Cathine ((+)-norpseudoephedrine);
1041 (b) Diethylpropion;
1042 (c) Fencamfamin;
1043 (d) Fenproporex;
1044 (e) Mazindol;
1045 (f) Mefenorex;
1046 (g) Modafinil;
1047 (h) Pemoline, including organometallic complexes and
1048 chelates thereof;
1049 (i) Phentermine;
1050 (j) Pipradrol;
1051 (k) Sibutramine;
1052 (l) SPA ((-)-1-dimethyamino-1,2-diphenylethane);
1053 (6) Any material, compound, mixture or preparation
1054 containing any quantity of the following substance,
1055 including its salts:
1056 (a) Butorphanol (including its optical isomers);
1057 (b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-
1058 2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H-
1059 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid)
SB 1165 35
1060 (including its optical isomers) and its salts, isomers, and
1061 salts of isomers;
1062 (c) Pentazocine;
1063 (7) Ephedrine, its salts, optical isomers and salts of
1064 optical isomers, when the substance is the only active
1065 medicinal ingredient;
1066 (8) The department of health and senior services may
1067 except by rule any compound, mixture, or preparation
1068 containing any depressant substance listed in subdivision
1069 (1) of this subsection from the application of all or any
1070 part of sections 195.010 to 195.320 and sections 579.015 to
1071 579.086 if the compound, mixture, or preparation contains
1072 one or more active medicinal ingredients not having a
1073 depressant effect on the central nervous system, and if the
1074 admixtures are included therein in combinations, quantity,
1075 proportion, or concentration that vitiate the potential for
1076 abuse of the substances which have a depressant effect on
1077 the central nervous system.
1078 9. The department of health and senior services shall
1079 place a substance in Schedule V if it finds that:
1080 (1) The substance has low potential for abuse relative
1081 to the controlled substances listed in Schedule IV;
1082 (2) The substance has currently accepted medical use
1083 in treatment in the United States; and
1084 (3) The substance has limited physical dependence or
1085 psychological dependence liability relative to the
1086 controlled substances listed in Schedule IV.
1087 10. The controlled substances listed in this
1088 subsection are included in Schedule V:
1089 (1) Any compound, mixture or preparation containing
1090 any of the following narcotic drugs or their salts
1091 calculated as the free anhydrous base or alkaloid, in
SB 1165 36
1092 limited quantities as set forth below, which also contains
1093 one or more nonnarcotic active medicinal ingredients in
1094 sufficient proportion to confer upon the compound, mixture
1095 or preparation valuable medicinal qualities other than those
1096 possessed by the narcotic drug alone:
1097 (a) Not more than two and five-tenths milligrams of
1098 diphenoxylate and not less than twenty-five micrograms of
1099 atropine sulfate per dosage unit;
1100 (b) Not more than one hundred milligrams of opium per
1101 one hundred milliliters or per one hundred grams;
1102 (c) Not more than five-tenths milligram of difenoxin
1103 and not less than twenty-five micrograms of atropine sulfate
1104 per dosage unit;
1105 (2) Any material, compound, mixture or preparation
1106 which contains any quantity of the following substance
1107 having a stimulant effect on the central nervous system
1108 including its salts, isomers and salts of isomers:
1109 pyrovalerone;
1110 (3) Any compound, mixture, or preparation containing
1111 any detectable quantity of pseudoephedrine or its salts or
1112 optical isomers, or salts of optical isomers or any
1113 compound, mixture, or preparation containing any detectable
1114 quantity of ephedrine or its salts or optical isomers, or
1115 salts of optical isomers;
1116 (4) Unless specifically exempted or excluded or unless
1117 listed in another schedule, any material, compound, mixture,
1118 or preparation which contains any quantity of the following
1119 substances having a depressant effect on the central nervous
1120 system, including its salts:
1121 (a) Brivaracetam ((25)-2-[(4R)-2-oxo-4-
1122 propylpyrrolidin-1-yl]butanamide) (also referred to as BRV;
1123 UCB-34714; Briviact);
SB 1165 37
1124 (b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-
1125 phenyl]-carbamic acid ethyl ester];
1126 (c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
1127 propionamide];
1128 (d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
1129 acid];
1130 (5) Any drug product in finished dosage formulation
1131 that has been approved by the U.S. Food and Drug
1132 Administration that contains cannabidiol (2-[1R-3-methyl-6R-
1133 (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-
1134 benzenediol) derived from cannabis and no more than 0.1
1135 percent (w/w) residual tetrahydro cannabinols.
1136 11. If any compound, mixture, or preparation as
1137 specified in subdivision (3) of subsection 10 of this
1138 section is dispensed, sold, or distributed in a pharmacy
1139 without a prescription:
1140 (1) All packages of any compound, mixture, or
1141 preparation containing any detectable quantity of
1142 pseudoephedrine, its salts or optical isomers, or salts of
1143 optical isomers or ephedrine, its salts or optical isomers,
1144 or salts of optical isomers, shall be offered for sale only
1145 from behind a pharmacy counter where the public is not
1146 permitted, and only by a registered pharmacist or registered
1147 pharmacy technician; and
1148 (2) Any person purchasing, receiving or otherwise
1149 acquiring any compound, mixture, or preparation containing
1150 any detectable quantity of pseudoephedrine, its salts or
1151 optical isomers, or salts of optical isomers or ephedrine,
1152 its salts or optical isomers, or salts of optical isomers
1153 shall be at least eighteen years of age; and
1154 (3) The pharmacist, intern pharmacist, or registered
1155 pharmacy technician shall require any person, prior to such
SB 1165 38
1156 person's purchasing, receiving or otherwise acquiring such
1157 compound, mixture, or preparation to furnish suitable photo
1158 identification that is issued by a state or the federal
1159 government or a document that, with respect to
1160 identification, is considered acceptable and showing the
1161 date of birth of the person;
1162 (4) The seller shall deliver the product directly into
1163 the custody of the purchaser.
1164 12. Pharmacists, intern pharmacists, and registered
1165 pharmacy technicians shall implement and maintain an
1166 electronic log of each transaction. Such log shall include
1167 the following information:
1168 (1) The name, address, and signature of the purchaser;
1169 (2) The amount of the compound, mixture, or
1170 preparation purchased;
1171 (3) The date and time of each purchase; and
1172 (4) The name or initials of the pharmacist, intern
1173 pharmacist, or registered pharmacy technician who dispensed
1174 the compound, mixture, or preparation to the purchaser.
1175 13. Each pharmacy shall submit information regarding
1176 sales of any compound, mixture, or preparation as specified
1177 in subdivision (3) of subsection 10 of this section in
1178 accordance with transmission methods and frequency
1179 established by the department by regulation;
1180 14. No person shall dispense, sell, purchase, receive,
1181 or otherwise acquire quantities greater than those specified
1182 in this chapter.
1183 15. All persons who dispense or offer for sale
1184 pseudoephedrine and ephedrine products in a pharmacy shall
1185 ensure that all such products are located only behind a
1186 pharmacy counter where the public is not permitted.
SB 1165 39
1187 16. The penalties for a knowing or reckless violation
1188 of the provisions of subsections 11 to 15 of this section
1189 are found in section 579.060.
1190 17. The scheduling of substances specified in
1191 subdivision (3) of subsection 10 of this section and
1192 subsections 11, 12, 14, and 15 of this section shall not
1193 apply to any compounds, mixtures, or preparations that are
1194 in liquid or liquid-filled gel capsule form or to any
1195 compound, mixture, or preparation specified in subdivision
1196 (3) of subsection 10 of this section which must be
1197 dispensed, sold, or distributed in a pharmacy pursuant to a
1198 prescription.
1199 18. The manufacturer of a drug product or another
1200 interested party may apply with the department of health and
1201 senior services for an exemption from this section. The
1202 department of health and senior services may grant an
1203 exemption by rule from this section if the department finds
1204 the drug product is not used in the illegal manufacture of
1205 methamphetamine or other controlled or dangerous
1206 substances. The department of health and senior services
1207 shall rely on reports from law enforcement and law
1208 enforcement evidentiary laboratories in determining if the
1209 proposed product can be used to manufacture illicit
1210 controlled substances.
1211 19. The department of health and senior services shall
1212 revise and republish the schedules annually.
1213 20. The department of health and senior services shall
1214 promulgate rules under chapter 536 regarding the security
1215 and storage of Schedule V controlled substances, as
1216 described in subdivision (3) of subsection 10 of this
1217 section, for distributors as registered by the department of
1218 health and senior services.
SB 1165 40
1219 21. Logs of transactions required to be kept and
1220 maintained by this section and section 195.417 shall create
1221 a rebuttable presumption that the person whose name appears
1222 in the logs is the person whose transactions are recorded in
1223 the logs.
1 195.810. 1. Notwithstanding any other provision of
2 law to the contrary, no state agency, including employees
3 therein, shall disclose to the federal government, any
4 federal government employee, or any unauthorized third party
5 the statewide list or any individual information of persons
6 who have applied for or obtained a qualifying patient
7 identification card, a qualifying patient cultivation
8 identification card, or a primary caregiver identification
9 card, as those cards are described in Article XIV, Section 1
10 of the Constitution of Missouri relating to the right to
11 access medical marijuana.
12 2. Any person who knowingly violates the provisions of
13 this section shall be guilty of a class E felony.
